Site reactions in peripheral fosaprepitant infusions

0

To verify the incidence of infusion site reactions and the relationship among risk factors, a quantitative retrospective cohort study was undertaken” Gonçalves et al (2017).

Abstract:

Fosaprepitant is administered intravenously to treat chemotherapy-induced nausea and vomiting. To verify the incidence of infusion site reactions and the relationship among risk factors, a quantitative retrospective cohort study was undertaken. The study included patients seen between October 2013 and February 2014. Fifty-seven patients were included in the study, and there were 105 infusions among them. Infusion site reactions were identified in 42 (40%) cases. Risk factors identified by the study included age (P < .001), insertion at the back of the hand and wrist (P < .001), and first fosaprepitant administration (P < .001). The study found evidence of a higher incidence of infusion site reactions than was reported in the package insert.

Reference:

Gonçalves, S.C., Sanches, S.M., Bueno, C.T., Villela de Castro, D.L., Damascena, A. and Santos, G.R.C. (2017) Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions. Journal of Infusion Nursing. 40(6), p.380-383.

doi: 10.1097/NAN.0000000000000252.

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.